1995
DOI: 10.1002/mpo.2950240409
|View full text |Cite
|
Sign up to set email alerts
|

Reversible thrombocytopenia with levamisole

Abstract: Levamisole is an immunomodulatory agent which is used in the adjuvant therapy of certain malignancies. Agranulocytosis is the most commonly reported hematologic side effect associated with this drug. We report here a patient who developed thrombocytopenia nearly 2 years after starting adjuvant levamisole therapy for malignant melanoma. In this case, thrombocytopenia was shown to be levamisole-related by rechallenge with the drug. Levamisole-induced thrombocytopenia (LIT) has been rarely diagnosed, but may be s… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
5
0

Year Published

1995
1995
2021
2021

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(5 citation statements)
references
References 13 publications
0
5
0
Order By: Relevance
“…The predominant adverse effects observed with it are haematological: agranulocytosis, leucopenia1 5 9–12; immunological: cutaneous vasculopathy, vasculitis and pseudovasculitis2 5 7 13 14 and neurological: multifocal inflammatory leucoencephalopathy 5 9 15 16. Other adverse effects that have been described are thrombocytopaenia,10 17–19 aplastic anaemia,4 pulmonary hypertension,4 renal failure,15 20 21 acute coronary syndrome,22 headaches and arthralgias 5. Among these, agranulocytosis is the most common adverse effect noted, followed by vasculopathy 23.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The predominant adverse effects observed with it are haematological: agranulocytosis, leucopenia1 5 9–12; immunological: cutaneous vasculopathy, vasculitis and pseudovasculitis2 5 7 13 14 and neurological: multifocal inflammatory leucoencephalopathy 5 9 15 16. Other adverse effects that have been described are thrombocytopaenia,10 17–19 aplastic anaemia,4 pulmonary hypertension,4 renal failure,15 20 21 acute coronary syndrome,22 headaches and arthralgias 5. Among these, agranulocytosis is the most common adverse effect noted, followed by vasculopathy 23.…”
Section: Discussionmentioning
confidence: 99%
“…Agranulocytosis is seen in 2.5%–13% of the patients using Lm as an immunomodulator 1. Lm has also rarely been reported to cause thrombocytopaenia 10 17–19. The precise mechanism by which Lm induces agranulocytosis has not been elucidated.…”
Section: Discussionmentioning
confidence: 99%
“…As a chemotherapeutic and immunomodulatory agent, adverse effects from levamisole ingestion include thrombocytopenia, microvascular thrombosis resulting in formation of palpable purpura, vasculitis, and ulcers of the mouth and skin . The purpura that results seem to have a predilection for involving the ear lobes .…”
Section: Discussionmentioning
confidence: 99%
“…6 Reversible thrombocytopenia and arthritis have also been reported. 1,7 There are currently no standardized diagnostic criteria.…”
Section: Discussionmentioning
confidence: 99%